This guide provides clinicians with an overview of drug-resistant tuberculosis. The guide includes tools that can be used by providers who participate in the management of patients with drug-resistant TB.
Favorite
Civil Surgeons
Nurses
Physicians
2022
This guide details 2020 updates to the WHO guidelines about the global standard of care for drug-resistant TB. The guide also includes messaging and strategies that can be used to advocate for WHO-recommended regimens.
Favorite
International Agencies
Policy Makers
2020
This document informs national TB programs and stakeholders about the key implications for the treatment of drug-resistant tuberculosis. This resource is available before the release of the updated guidelines in order for planning at the country level. The guidelines are expected to be released in 2020...
Favorite
Physicians
International Agencies
2019
This report analyses the factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. Detailed pricing profiles of key DR-TB drugs are also provided.
Favorite
International Agencies
Policy Makers
2016
This information sheet discusses the challenges and key issues of the co-infection of TB and HIV. It states that TB is the leading cause of the death among people with HIV.
Favorite
2014
This report highlights the issues surrounding high prices and poor supply of the drugs needed to treat drug-resistant tuberculosis (DR-TB). The report provides an overview of available drug-resistant TB medicines, including drug sources, quality status, and price.
Favorite
International Agencies
Policy Makers
2013
This fact sheet provides an overview of multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB). This fact sheet covers definitions, symptoms, treatment, transmission, and prevention.
Favorite
2012
This new report on anti-tuberculosis (TB) drug resistance by the World Health Organization (WHO) updates “Anti-tuberculosis drug resistance in the world: Report No. 4” published by WHO in 2008. It summarizes the latest data and provides latest estimates of the global epidemic of multidrug and extensively drug-resistant tuberculosis (M/XDR-TB)...
Favorite
International Agencies
Policy Makers
2010
The Global Drug Facility (GDF) is a mechanism to expand access to, and availability of, high-quality anti-TB drugs and diagnostics to support the Stop TB Strategy.
This document outlines progress that GDF has made to date, what still needs to be done and where high-level advocacy could help GDF to further scale up its activities.
Favorite
International Agencies
Policy Makers
2010
This tool will assist countries and partners in conducting assessments of national tuberculosis (TB) programs to identify strengths and gaps related to preventing, diagnosing, and treating multidrug-resistant TB. It provides the starting point for planning for new activities to address drug-resistant TB...
Favorite
International Agencies
Managers and Supervisors
2009
This booklet calls upon national programs for TB control, donors, financing institutions, civil society, media, and communities to join hands in intensifying the fight against drug-resistant TB.
Favorite
International Agencies
Policy Makers
2009
This fact sheet covers frequently asked questions regarding extensively drug-resistant tuberculosis (XDR-TB). Information on the medical definition, transmission, symptoms, diagnosis, treatment, and prevention are included. The fact sheet also addresses travel safety, the link to HIV/AIDS, and WHO's actions to combat XDR-TB.
Favorite
International Agencies
2006
